Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer
The XELOXIRI regimen demonstrated promising efficacy and manageable toxicity in the treatment of APC, providing a practical alternative to FOLFOXIRI, with similar outcomes and easier administration.
Authors
- Wenwei Yang (ORCID: https://orcid.org/0000-0002-7292-5980)
- Kai Ou (ORCID: https://orcid.org/0000-0003-2762-6719)
- Letian Zhang (ORCID: https://orcid.org/0000-0002-3373-5615)
- Qi Cao (ORCID: https://orcid.org/0000-0002-5140-3681)
- Xiaoting Ma (ORCID: https://orcid.org/0000-0003-1329-9761)
- Biyang Cao
- Zhichao Jiang (ORCID: https://orcid.org/0000-0003-0092-1494)
- Qi Wang (ORCID: https://orcid.org/0000-0003-4436-8694)
- Jie Zhang (ORCID: https://orcid.org/0000-0002-0466-2955)
- Wen Zhang (ORCID: https://orcid.org/0000-0002-3247-9672)
- Jingyu Lu
- Lizhen Gao (ORCID: https://orcid.org/0000-0003-0850-736X)
- Lin Yang (ORCID: https://orcid.org/0009-0005-6756-1683)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1186/s12885-025-13799-5
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05